Founded in 2015, New Horizon Health Limited (SEHK:6606) is a pioneer in China’s colorectal cancer screening market, focusing on high-incidence cancers and home-based early detection. The company’s mission is to advance innovation and accelerate the adoption of cancer screening technologies in China. It has developed two National Medical Products Administration (NMPA)-approved colorectal cancer screening tests: ColoClear® and Pupu Tube®. ColoClear® is notably the first and only cancer screening test in China approved by the NMPA. Additionally, New Horizon Health has two late-stage pipeline candidates for gastric and cervical cancer screening, with global rights to all its marketed and pipeline products.  

 

The company has also attracted investments from other reputable venture capital and private equity firms, including VMS Group, Qiming Venture Partners, Legend Capital, and SoftBank China. On February 18, 2021, New Horizon Health became the first Chinese cancer early screening company to be listed on the Main Board of the Hong Kong Stock Exchange.